Brainstorm Cell Therapeutics Files 8-K

TL;DR

Brainstorm Cell Therapeutics filed an 8-K on Aug 14, 2025, updating on financials.

AI Summary

On August 14, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing indicates the company's financial condition and results of operations, with no specific financial figures or events detailed in the provided text.

Why It Matters

This 8-K filing signals a routine update on the company's financial status and operational results, which is important for investors to monitor.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for results of operations and financial condition, with no immediate negative or positive indicators in the provided text.

Key Players & Entities

• BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
• August 14, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-36641 (commission_file_number) — SEC File Number
• 20-7273918 (irs_ein) — IRS Employer Identification Number

FAQ

Key Financial Figures

• $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI OTCQB Venture Market

Filing Documents

• tm2523508d1_8k.htm (8-K) — 24KB
• tm2523508d1_ex99-1.htm (EX-99.1) — 81KB
• tm2523508d1_ex99-1img01.jpg (GRAPHIC) — 9KB
• 0001104659-25-078116.txt ( ) — 290KB
• bcli-20250814.xsd (EX-101.SCH) — 3KB
• bcli-20250814_lab.xml (EX-101.LAB) — 33KB
• bcli-20250814_pre.xml (EX-101.PRE) — 22KB
• tm2523508d1_8k_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On August 14, 2025, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by Brainstorm Cell Therapeutics Inc. on August 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: August 14, 2025 By: /s/ Chaim Lebovits Chaim Lebovits President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR